While the glycemic effects of GIP receptor (GIPR) agonism are solidly confirmed, uncertainty exists as to whether GIPR should be stimulated or inhibited for the treatment of type 2 diabetes mellitus (T2DM) and obesity (Holst and Rosenkilde, 2020). Here, GIPR is linked to obesity disorder.